Cancer research is one of the last areas of human endeavor in which anyone would want to “cut corners.” Yet, that’s exactly what scientists must often do when the computational resources available to them aren’t sufficient to handle all the components of experiments they want to run. That is the problem described by Ramy Farid, president of a New York firm called Schrödinger that makes simulation software for use in pharmaceutical and biotechnology research. The company operates a 1,500-core cluster to perform research, but it’s often not enough.
